期刊文献+

左甲状腺素钠治疗老年甲状腺功能减退综合征疗效观察及安全性研究 被引量:30

左甲状腺素钠治疗老年甲状腺功能减退综合征疗效观察及安全性研究
下载PDF
导出
摘要 目的探讨左甲状腺素钠治疗老年甲状腺功能减退症的疗效及安全性。方法选取2009年3月~2010年11月湖南省洪江市人民医院治疗的甲状腺功能减退老年患者64例,随机分为两组,各32例。对照组采用甲状腺片治疗,治疗组采用左甲状腺素钠治疗。对比分析两组患者治疗前后的TSH、FT4及FT3差异及不良反应情况。结果两组患者的TSH、FT4及FT3水平均较治疗前明显改善,但治疗组TSH恢复所用时间较短,且治疗组不良反应发生率较对照组低,差异有统计学意义(P<0.05)。结论左甲状腺素钠治疗老年甲状腺功能减退症十分有效,且效价稳定,不良反应少,是一种安全有效的治疗甲状腺功能减退症药物。 Objective To investigate the clinical efficacy and safety of levothyroxine sodium in the treatment of elderly hypothyroidism. Methods 64 hypothyroidismL elderly patients were chosen in our hospital from March 2009 to November 2010, they were randomLy divided into control and treatment group, 32 cases in each group, control group patients with the treatment of thyroid tablets, treatment group patients with levothyroxine sodium therapy, comparative analysis of two groups patients' TSH, FT4 and FT3 difference before and after treatment, and adverse reactions.Results The two groups patients' TSH, FT4 and FT3 levels improved significantly after treatment and the TSH recovery time of treatment group is shorter and with less adverse reactions compared with the control group (P〈0.05). Conclusion Levothyroxine sodium in the treatment of elderly hypothyroidism is very effective, stable titer less adverse reactions,it is a safe effective treatment of hypothyroidism drugs.
作者 王应菊
出处 《当代医学》 2012年第32期84-85,共2页 Contemporary Medicine
关键词 左甲状腺素钠 甲状腺功能减退症 安全性 Levothyroxine sodium Hypothyroidism Security
  • 相关文献

参考文献6

二级参考文献25

  • 1刘建平,徐琳琳,张胜兰,王虹,王兰.甲状腺功能亢进和减退症心脏损害病例的回顾性分析[J].实用医药杂志,2006,23(11):1323-1324. 被引量:3
  • 2闫朝丽,李珍珍,皇甫建.原发性甲状腺功能减退症误诊52例原因分析[J].疑难病杂志,2007,6(3):181-182. 被引量:16
  • 3史轶繁.激素与肝脏.协和内分泌和代谢学[M].北京:科学出版社,1999.1726-1733.
  • 4邓万俊.老年妇女甲状腺功能与血脂.国外医学:内科学分册,1999,25(9):408-408.
  • 5Chapidze G,Dolidze N,williams M,et al.Peculiarities of lipid profile parameters in cardiac patients with hypo-and hyperthy-roidism[J].GeorginaMedNews,2006,133:44-46.
  • 6Michalopoulou G,Alevizaki M,Piperingos G,et al.High serum cholesterol levels in persons with'high normal'TSH levels:shoud one extend the'definition of subclinical hypothyroidism[J].Eur J Endocrinol,1998,138:141-145.
  • 7Christ OrainM,M eier G.GuglielmettiM,et al.Elevated C reactive protein and homocysteine values:cardiovascular risk factors in hypothyroidism?A cross sectional and a double blind,placebo controlled trial[J].A therosclerosis,2003,188(22):379-386.
  • 8Ozcan O,Cakir E,Yaman H,et al.The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine(ADMA)and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism[J].Clin Endocrinol,2005,63(2):203-206.
  • 9ImaizumiM,AkahoshiM,Ichimaru S,et al.Risk for ischemic heart disease and all causemotality in subclinical hypothyroidism[J].Clin Endocrinol Metab,2004,89(7):3365-3370.
  • 10Peter Laurberg,Jens Faber.亚临床甲状腺疾病[C].内分泌论文专编,2002:4.

共引文献12

同被引文献139

引证文献30

二级引证文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部